<DOC>
	<DOCNO>NCT01466062</DOCNO>
	<brief_summary>To evaluate safety , efficacy pharmacokinetics palivizumab child age 24 month less immunocompromised medical condition .</brief_summary>
	<brief_title>Clinical Study Palivizumab Japanese Newborns , Infants Young Children Age 24 Months Less With Immunocompromised Medical Conditions</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>1 . Availability parent legal guardian capable willing give write informed consent his/her newborn , infant young child participate study . 2 . Japanese newborn , infant young child age 24 month less . 3 . The subject must meet least one follow immunocompromised medical condition ( [ ] [ h ] ) , must consider investigator suitable candidate receive prophylactic treatment palivizumab : 1 . Subject diagnose combined immunodeficiency ( severe combine immunodeficiency , Xlinked hyperimmunoglobulin M ( IgM ) syndrome , etc . ) , antibody deficiency ( Xlinked agammaglobulinemia , common variable immunodeficiency , nonXlinked hyperIgM syndrome , etc . ) immunodeficiency ( WiskottAldrich syndrome , DiGeorge syndrome , etc . ) time informed consent , 2 . Subject diagnosed human immunodeficiency virus infection , 3 . Subject diagnose Down syndrome without current hemodynamically significant congenital heart disease time inform consent ( subject must experience persistent respiratory symptom regular outpatient treatment due respiratory tract infection prior current RSV season ) , 4 . Subject history post organ transplantation time informed consent , 5 . Subject history post bone marrow transplantation time informed consent , 6 . Subject receive immunosuppressive chemotherapy start study drug administration , 7 . Subject receive systemic high dose corticosteroid therapy ( prednisone equivalent 0.5 mg/kg every day , inhaler topical use ) start study drug administration , 8 . Subject receive immunosuppressive therapy ( azathioprine , methotrexate , mizoribine , mycophenolate mofetil , cyclophosphamide , cyclosporine , tacrolimus , cytokine inhibitor , etc . ) start study drug administration . 1 . Subject meet one palivizumab indication already approve Japan . Subject bear 28 week gestation less age 12 month less start study drug administration . Subject bear 29 35 week gestation age 6 month less start study drug administration . Subject age 24 month less history bronchopulmonary dysplasia require medical management within 6 month prior study drug administration . Subject age 24 month less current hemodynamically significant congenital heart disease start study drug administration . 2 . Subject require oxygen supplementation , mechanical ventilation , extracorporeal membrane oxygenation , continuous positive airway pressure mechanical respiratory cardiac support Screening start study drug administration . 3 . Subject current active infection include respiratory syncytial virus infection Screening start study drug administration . 4 . Subject serious concurrent medical condition ( hepatic dysfunction , persistent seizure disorder , etc . ) except result immune deficiency condition renal failure . 5 . Subject receive palivizumab prior study drug administration . 6 . Subject receive investigational agent past 3 month 5 half life prior investigational drug administration ( whichever longer ) . 7 . Subject history allergic reaction hypersensitivity constituent study drug . 8 . Subject history serious adverse reaction serious allergic reaction immunoglobulin product history hypersensitivity immunoglobulin product , blood product , foreign protein . 9 . Subject whose remain day life expect less one year time informed consent . 10 . It impossible collect blood schedule subject . 11 . Subject consider investigator , reason , unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Immunocompromised medical condition</keyword>
	<keyword>Respiratory Syncytial Virus Infection</keyword>
	<keyword>Infant</keyword>
	<keyword>Newborn</keyword>
	<keyword>Young child</keyword>
</DOC>